Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

891
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
891
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.0K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Clinical Outcomes and Predictors of Retinal Breaks in Patients With Vitreous Hemorrhage Secondary to a Posterior Vitreous Detachment.

Journal of vitreoretinal diseases·2026
Same author

RPE With ROCK-Mediated Epithelial-Mesenchymal Transition as a Key Contributor of Subretinal Fibrosis in AMD.

Investigative ophthalmology & visual science·2026
Same author

Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial.

Expert opinion on biological therapy·2026
Same author

Aberrant retinal structure and vasculature in mouse models of dominant retinopathies caused by <i>CRX</i> homeodomain mutations.

bioRxiv : the preprint server for biology·2026
Same author

Energetic diversity in retinal ganglion cells is modulated by neuronal activity and correlates with resilience to degeneration.

Nature communications·2026
Same author

Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral Leukoencephalopathy.

Neurology·2026
Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026
Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026
Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
Same journal

Systematic discovery of pathogen effector functions across human pathogens and pathways.

Cell·2026
関連記事をすべて見る

関連する実験動画

Updated: Dec 25, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.6K

AMD の治療負担を軽減する

Rajendra S Apte1

  • 1Paul A. Cibis Distinguished Professor, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.

Cell
|March 24, 2020
PubMed
まとめ
この要約は機械生成です。

血管内皮成長因子A (VEGF-A) 反抗剤は,湿った年齢関連のマキュラ変性 (AMD) に新しい希望を提供します. ブロルチズマブは,アフリルセプトと比べ,視覚的な結果と,より優れた解剖学的結果を示し,治療の負担を軽減します.

さらに関連する動画

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

3.0K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.4K

関連する実験動画

Last Updated: Dec 25, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.6K
Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

3.0K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.4K

科学分野:

  • 眼科について
  • 医学 研究
  • 薬物開発

背景:

  • 血管内皮成長因子A (VEGF-A) 抗剤は,湿った年齢関連のマキュラ変性 (AMD) 治療に変化をもたらしました.
  • 持続的な湿ったAMDは,頻繁に眼内注射を必要とし,治療に重大な負担を伴う.

研究 の 目的:

  • 直接的なVEGF-A阻害剤であるブロルシズマブと,湿気性AMDの治療におけるアフリブレセプトの有効性を比較する.
  • 網膜液の減少を含む視覚的および解剖学的結果を評価する.

主な方法:

  • ブロルシズマブはVEGF-Aを直接抑制する.
  • ブロルチズマブとアフリベルセプトの治療群の視力および網膜液の測定値の比較

主要な成果:

  • ブロルチズマブは,アフリベルセプトに匹敵する視覚的結果を示した.
  • 解剖学的結果,特に網膜液の減少はブロルシズマブを好みました.

結論:

  • ブロルシズマブは湿気性AMDに対する有望な治療法です.
  • ブロルチズマブによる直接的なVEGF- A抑制は,解剖学的制御を改善し,治療の負担を軽減する可能性がある.